APOGEE BIOTECHNOLOGY CORPORATION
Opaganib (ABC294640), a first-in-class small-molecule SK2 inhibitor therapeutic for acute radiation syndrome and cancer
- Sector
- Biotech
- Headquarters
- Hummelstown, PA
- Total capital
- $7.8M
- Federal grants
- $4.8M
- 9 awards · 2015–2024
- Rank in peer group#183 of 514
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $3M
- 2 awards · Health and Human S
- Rank in Biotech#109 of 4373
- Granted patents
- 2
- 10 pending · first 2024
- Rank in peer group#142 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$883K
- Federal grantHealth and Human S · Phase II · Opaganib as a Medical Countermeasure for Gastrointestinal Acute Radiation Syndrome$852K
- Federal grantHealth and Human S · Phase I · Treatment of Neuroblastoma by Inhibition of Sphingosine Kinase$225K
- Federal grantHealth and Human S · Phase II · Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$653K
- Federal grantHealth and Human S · Phase II · An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re$133K
- Federal grantHealth and Human S · Phase II · Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$660K
- Federal grantHealth and Human S · Phase II · Clinical Trial of ABC294640 in Patients with Refractory Multiple Myeloma$667K
Show 4 earlier federal awards
- Federal grantHealth and Human S · Phase II · An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re$499K
- Federal grantHealth and Human S · Phase I · Radiosensitizing Prostate Cancer by Downregulation of Androgen Receptors and c-Myc$225K
- Federal contractHealth and Human S · Igf::ot::igf Modulation Of Cancer Radiotherapy By ABC294640$200K
- Federal contractHealth and Human S · Drugs And Biologicals$2.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#183 · top 36%
- Granted patents#142 · top 28%
- Linked publications#9 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 2 granted of 12- New patentCombination Of A SK2 Inhibitor And An Inhibitor Of A Checkpoint Pathway, Uses And Pharmaceutical Compositions ThereofUSPTOUS 12,758,536
- PendingCompositions And Methods For The Prevention And Treatment Of Obesity And Obesity-induced DiseaseUSPTOApplication 19045439
- GrantedSphingosine Kinase InhibitorsUSPTOUS RE49,811
Show all 12 patent records
- Combination Of A SK2 Inhibitor And An Inhibitor Of A Checkpoint Pathway, Uses And Pharmaceutical Compositions ThereofOct 13, 2026 · US 12,758,536Granted
- Compositions And Methods For The Prevention And Treatment Of Obesity And Obesity-induced DiseaseJun 11, 2026 · Application 19045439Pending
- Sphingosine Kinase InhibitorsJan 23, 2024 · US RE49,811Granted
- Combination Of A SK2 Inhibitor And An Inhibitor Of A Checkpoint Pathway, Uses And Pharmaceutical Compositions ThereofMar 3, 2022 · Application 17422647Pending
- Diaminothiazole Compounds, Compositions And Methods Of UseApplication 62421328Pending
- Sphingosine Kinase Inhibitor ProdrugsApplication PCTUS2010027177Pending
- Sphingosine Kinase Inhibitors And Methods Of Their UseApplication PCTUS2006030327Pending
- Sphingosine Kinase InhibitorsApplication PCTUS2006023645Pending
- Diaminothiazole Compounds, Compositions And Methods Of UseApplication PCTUS2017061327Pending
- Compositions And Methods For The Prevention And Treatment Of Obesity And Obesity-induced DiseaseApplication 63679916Pending
- Methods Of Inducing An Anti-cancer Immune ResponseApplication PCTUS2020013817Pending
- Compositions And Methods For The Prevention And Treatment Of Obesity And Obesity-induced DiseaseApplication PCTUS2025014499Pending
Recent research by its founders
- Celebrating 25 years of Impact and Long-Term Returns on Investment20260 cites
- Three-stage hybrid spiking neural networks fine-tuning for speech enhancement20251 cites
- Spiking neural networks fine-tuning for brain image segmentation202310 cites
Related companies, and why
- NEOVAXSYN INCSimilar federal contract value in Biotech · $3.2M in contracts
- BOLDER BIOTECHNOLOGY INCSimilar federal contract value in Biotech · $3.1M in contracts
- BIOMATRICA, INC.Similar federal contract value in Biotech · $3M in contracts
- AKINA, INC.Similar federal contract value in Biotech · $3M in contracts
- ACTIVE MOTIF, INC.Similar federal contract value in Biotech · $2.9M in contracts
- ARUNA BIO, INC.Similar federal contract value in Biotech · $2.9M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .